Sharafat Hussain: Understanding CD Markers in Modern Cancer Therapy
Sharafat Hussain explains the role of Cluster of Differentiation (CD) markers in oncology, clarifying how these surface proteins serve as targets for precision cancer therapies. The article distinguishes CD markers from other therapeutic targets like HER2 and EGFR.
Why it matters
Understanding these molecular markers is essential for grasping the mechanisms behind modern targeted cancer treatments and immunotherapy.
Sharafat Hussain , Zonal Sales Manager (North) Oncology at Revive Healthcare International, shared a post on LinkedIn :
”What Does ‘CD’ Mean in Oncology? Understanding the Language Behind Targeted Cancer Therapy.
If you’ve ever read about targeted cancer therapies, you’ve probably come across statements such as:
For many healthcare professionals and students, the obvious question is:
CD stands for Cluster of Differentiation.
These are specific proteins found on the surface of cells that act as biological identification markers. Think of them as the molecular ID cards of our cells. Different cell types express different combinations of CD markers, allowing scientists and clinicians to identify them accurately.
Beyond identifying cells, these markers have become some of the most important therapeutic targets in modern oncology.
One common misconception is that all therapeutic targets are CD markers . This is not the case.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in